|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase II Study of Hycanthone for Metastatic Breast Cancer
Basic Trial Information
Objectives I. Determine effect of hycanthone on metastatic carcinoma of the breast. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with measurable indicator lesions of metastatic breast carcinoma who have failed on first and second order protocols, with a life expectancy of at least 8 weeks and a Karnofsky performance score above 30. Patients with bone metastases must have clearly defined lytic disease; and patients with liver metastases must have normal transaminase and serum bilirubin level. Expected Enrollment Protocol closed 09/79. Outline Nonrandomized study. Regimen A: Single-agent Chemotherapy. Hycanthone mesylate, NSC-142982. Trial Lead Organizations M. D. Anderson Cancer Center at University of Texas
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |